Axogen, Inc.
AXGNHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, Axogen, Inc. (AXGN) is listed under Medical Devices. With a market capitalization of $2.12B, it sits in mid-cap territory. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
Market Cap
$2.12B
Beta
1.09
P/E (TTM)
—
P/E (Fwd)
54.71
EPS (TTM)
$-0.64
EPS (Fwd)
$0.73
ROE
-18.0%
ROA
-2.3%
Cash
$101.6M
Total Debt
$20.6M
Free CF
$18.3M
52W Change
253.3%
Annual Financials
Cash vs Debt
Axogen, Inc. holds $101.6M in cash against $20.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $18.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -18.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $127.4M (2021) to $225.2M (2025), reflecting a 77% increase over the period.
With cash comfortably exceeding debt, AXGN has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing AXGN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.